UBR5 Antibody [A19C24]

Catalog No.: F9843

Application: Reactivity: Human, Mouse, Rat, Monkey

Lane 1: HT1080, Lane 2: MCF7, Lane 3: SH-SY5Y, Lane 4: COS-7

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:50

Application
WB, IP

Source
Rabbit Monoclonal Antibody

Reactivity
Human, Mouse, Rat, Monkey

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
300 kDa

Datasheet & SDS

生物学的記述

Specificity
UBR5 Antibody [A19C24] detects endogenous levels of total UBR5 protein.

Clone
A19C24

Synonym(s)
E3 ubiquitin-protein ligase UBR5; E3 ubiquitin-protein ligase, HECT domain-containing 1; Hyperplastic discs protein homolog; hHYD; Progestin-induced protein; UBR5; EDD; EDD1; HYD; KIAA0896

Background
UBR5, a HECT-domain E3 ubiquitin ligase within the N-recognin family of the N-end rule pathway, orchestrates targeted protein degradation to maintain cellular signaling homeostasis through its UBR and WWE domains that flank the catalytic HECT lobe for precise substrate recognition. In the DNA damage response, UBR5 ubiquitinates RNF8 and RNF168 to restrict their accumulation at double-strand breaks, preventing excessive H2A/H2AX ubiquitination while enabling controlled 53BP1 recruitment through RNF168 turnover, thereby integrating with ATM/CHK2 signaling and stabilizing TopBP1 to support replication fork progression. Loss of UBR5 triggers RNF168 hyperaccumulation, fork collapse, and hypersensitivity to doxorubicin due to homologous recombination defects involving RAD51 and BRCA1. In triple-negative breast cancer, UBR5 drives aggressive progression by polyubiquitinating E-cadherin for lysosomal degradation, thereby activating β-catenin/TCF-mediated transcription that fuels proliferation, angiogenesis, and lung metastasis, even as it paradoxically recruits CD8+ T cells via type I interferon signaling without curbing tumor outgrowth. UBR5 fine-tunes Th17 cell differentiation by targeting RORγt for proteasomal degradation, counterbalancing DUBA-mediated deubiquitination to limit IL-17-driven intestinal inflammation. UBR5 links proteostasis to epithelial and neuronal cell polarity via N-degron substrates, with its amplification correlating to poor survival in breast and ovarian cancers owing to pro-metastatic roles in polarized contexts.

Background

UBR5, a HECT-domain E3 ubiquitin ligase within the N-recognin family of the N-end rule pathway, orchestrates targeted protein degradation to maintain cellular signaling homeostasis through its UBR and WWE domains that flank the catalytic HECT lobe for precise substrate recognition. In the DNA damage response, UBR5 ubiquitinates RNF8 and RNF168 to restrict their accumulation at double-strand breaks, preventing excessive H2A/H2AX ubiquitination while enabling controlled 53BP1 recruitment through RNF168 turnover, thereby integrating with ATM/CHK2 signaling and stabilizing TopBP1 to support replication fork progression. Loss of UBR5 triggers RNF168 hyperaccumulation, fork collapse, and hypersensitivity to doxorubicin due to homologous recombination defects involving RAD51 and BRCA1. In triple-negative breast cancer, UBR5 drives aggressive progression by polyubiquitinating E-cadherin for lysosomal degradation, thereby activating β-catenin/TCF-mediated transcription that fuels proliferation, angiogenesis, and lung metastasis, even as it paradoxically recruits CD8+ T cells via type I interferon signaling without curbing tumor outgrowth. UBR5 fine-tunes Th17 cell differentiation by targeting RORγt for proteasomal degradation, counterbalancing DUBA-mediated deubiquitination to limit IL-17-driven intestinal inflammation. UBR5 links proteostasis to epithelial and neuronal cell polarity via N-degron substrates, with its amplification correlating to poor survival in breast and ovarian cancers owing to pro-metastatic roles in polarized contexts.

References
[1] Kumar R, et al. Trends Immunol. 2021 Nov;42(11):1037-1050. [2] Liao L, et al. Cancer Res. 2017 Apr 15;77(8):2090-2101.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%